138 related articles for article (PubMed ID: 36244195)
1. FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope?
Helal C; Valéry M; Ducreux M; Hollebecque A; Smolenschi C
Eur J Cancer; 2022 Nov; 176():168-170. PubMed ID: 36244195
[No Abstract] [Full Text] [Related]
2. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.
Ng CF; Glaspy J; Placencio-Hickok VR; Thomassian S; Gong J; Osipov A; Hendifar AE; Moshayedi N
J Natl Compr Canc Netw; 2022 Oct; 20(10):1076-1079. PubMed ID: 36240849
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic strategy for intractable pancreatic cancer and its fundamental research.
Cho K; Ishiwata T; Naito Z; Uchida E
J Nippon Med Sch; 2010 Feb; 77(1):62-3. PubMed ID: 20154464
[No Abstract] [Full Text] [Related]
4. FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer.
Nomura S; Yoshitomi H; Takano S; Shida T; Kobayashi S; Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Kato A; Miyazaki M
Br J Cancer; 2008 Jul; 99(2):305-13. PubMed ID: 18594526
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer.
Matsuda Y; Yoshimura H; Suzuki T; Uchida E; Naito Z; Ishiwata T
Cancer Sci; 2014 Sep; 105(9):1212-9. PubMed ID: 24975163
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
Ruess DA; Görgülü K; Wörmann SM; Algül H
Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
[TBL] [Abstract][Full Text] [Related]
7. Stage 4 pancreatic adenocarcinoma harbouring an
Poon D; Tan MH; Khor D
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34511423
[TBL] [Abstract][Full Text] [Related]
8. The pathology of ductal-type pancreatic carcinomas and pancreatic intraepithelial neoplasia: insights for clinicians.
Klöppel G; Lüttges J
Curr Gastroenterol Rep; 2004 Apr; 6(2):111-8. PubMed ID: 15191688
[TBL] [Abstract][Full Text] [Related]
9. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer.
Zhang Z; Qin Y; Ji S; Xu W; Liu M; Hu Q; Ye Z; Fan G; Yu X; Liu W; Xu X
Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(8):997-1008. PubMed ID: 34117747
[TBL] [Abstract][Full Text] [Related]
10. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
11. RUNX3 Modulates Metastatic Potential in Pancreatic Ductal Adenocarcinoma.
Cancer Discov; 2015 Jul; 5(7):OF27. PubMed ID: 26045017
[TBL] [Abstract][Full Text] [Related]
12. Mast cells and angiogenesis in pancreatic ductal adenocarcinoma.
Longo V; Tamma R; Brunetti O; Pisconti S; Argentiero A; Silvestris N; Ribatti D
Clin Exp Med; 2018 Aug; 18(3):319-323. PubMed ID: 29492715
[TBL] [Abstract][Full Text] [Related]
13. Controversy on the time to progression of pancreatic ductal adenocarcinoma.
Gallmeier E; Hernaez R; Gress TM
Gut; 2015 Nov; 64(11):1676-7. PubMed ID: 25731873
[No Abstract] [Full Text] [Related]
14. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN.
Yamaguchi K; Kanemitsu S; Hatori T; Maguchi H; Shimizu Y; Tada M; Nakagohri T; Hanada K; Osanai M; Noda Y; Nakaizumi A; Furukawa T; Ban S; Nobukawa B; Kato Y; Tanaka M
Pancreas; 2011 May; 40(4):571-80. PubMed ID: 21499212
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
16. Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma.
Berchtold S; Grünwald B; Krüger A; Reithmeier A; Hähl T; Cheng T; Feuchtinger A; Born D; Erkan M; Kleeff J; Esposito I
Cancer Lett; 2015 Jan; 356(2 Pt B):721-32. PubMed ID: 25449434
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic Ductal Adenocarcinoma.
Erickson LA
Mayo Clin Proc; 2017 Sep; 92(9):1461-1462. PubMed ID: 28870368
[No Abstract] [Full Text] [Related]
18. HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line.
Gower WR; Risch RM; Godellas CV; Fabri PJ
In Vitro Cell Dev Biol Anim; 1994 Mar; 30A(3):151-61. PubMed ID: 25939163
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Potential for FGFR Inhibitors in SOX9-FGFR2 Coexpressing Pancreatic Cancer.
OʼSullivan H; Kelleher FC; Lavelle M; McGovern B; Murphy J; Swan N; McDermott R
Pancreas; 2017 Sep; 46(8):e67-e69. PubMed ID: 28796141
[No Abstract] [Full Text] [Related]
20. MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor.
Chen Y; Zhu H; Wang Y; Song Y; Zhang P; Wang Z; Gao J; Li Z; Du Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033818824314. PubMed ID: 30803373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
